Cis-eligible Muscle-invasive bladder cancer. research hub

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)

This study is testing if adding a new drug, pembrolizumab (Keytruda), to standard chemotherapy before and after surgery can help people with a type of bladder cancer. Researchers want to see if this combination works better than chemotherapy alone to keep the cancer away.